Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.

ABSTRACT:

Background

The emergence of integrase strand-transfer inhibitor (INSTI) resistance-associated mutations was examined in patients with low-level viremia after switching from enfuvirtide to raltegravir in the ANRS 138-Easier trial.

Methods

Integrase genes of plasma virus from raltegravir-treated patients in the Easier trial with low-level viremia (50-500 copies/ml) were sequenced to determine INSTI resistance-associated mutations. Baseline viral load, baseline and nadir CD4 cell count, antiretroviral treatment, genotypic susceptibility score, level of viremia and degree of treatment adherence during the study period were also analyzed.

Results

Forty-nine patients experienced at least one episode of low-level viremia while receiving raltegravir; integrase genotyping was

SUBMITTER: Gallien S 

PROVIDER: S-EPMC3265637 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature